DarioHealth Corp. (NASDAQ:DRIO – Free Report) – Investment analysts at Litchfield Hills Research lowered their FY2025 earnings per share estimates for DarioHealth in a research report issued to clients and investors on Thursday, January 22nd. Litchfield Hills Research analyst T. O’neill now forecasts that the company will post earnings of ($12.36) per share for the year, down from their previous forecast of ($12.34). The consensus estimate for DarioHealth’s current full-year earnings is ($1.18) per share. Litchfield Hills Research also issued estimates for DarioHealth’s Q4 2025 earnings at ($1.80) EPS, Q1 2026 earnings at ($1.31) EPS, Q2 2026 earnings at ($1.11) EPS, Q3 2026 earnings at ($0.85) EPS, Q4 2026 earnings at ($0.62) EPS and FY2026 earnings at ($4.00) EPS.
A number of other brokerages have also weighed in on DRIO. Weiss Ratings reiterated a “sell (d-)” rating on shares of DarioHealth in a research report on Monday, December 29th. Wall Street Zen downgraded shares of DarioHealth from a “hold” rating to a “sell” rating in a report on Sunday. TD Cowen reiterated a “hold” rating on shares of DarioHealth in a research note on Friday, November 14th. Finally, Stifel Nicolaus set a $16.00 target price on shares of DarioHealth in a report on Friday, November 14th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, DarioHealth currently has an average rating of “Hold” and a consensus price target of $32.00.
DarioHealth Stock Down 2.1%
DRIO stock opened at $11.40 on Monday. The stock has a fifty day moving average of $11.94 and a 200-day moving average of $11.96. DarioHealth has a fifty-two week low of $5.93 and a fifty-two week high of $17.74. The company has a market capitalization of $77.06 million, a price-to-earnings ratio of -1.02 and a beta of 1.05. The company has a debt-to-equity ratio of 0.41, a quick ratio of 4.02 and a current ratio of 4.55.
Hedge Funds Weigh In On DarioHealth
A hedge fund recently raised its stake in DarioHealth stock. XTX Topco Ltd raised its holdings in DarioHealth Corp. (NASDAQ:DRIO – Free Report) by 229.0% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 62,511 shares of the company’s stock after acquiring an additional 43,513 shares during the period. XTX Topco Ltd owned approximately 0.14% of DarioHealth worth $42,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 33.39% of the company’s stock.
About DarioHealth
DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.
The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.
See Also
- Five stocks we like better than DarioHealth
- How a Family Trust May Be Able To Help Preserve Your Wealth
- NEW LAW: Congress Approves Setup For Digital Dollar?
- The $100 Trillion AI Story No One Is Telling You
- If You Keep Cash In A U.S. Bank Account… Read This NOW
- A U.S. “birthright” claim worth trillions – activated quietly
Receive News & Ratings for DarioHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DarioHealth and related companies with MarketBeat.com's FREE daily email newsletter.
